Typing TPMT and ITPase to detect azathioprine toxicity

被引：6

作者：

Arenas, Monica

Marinaki, Anthony

Ansari, Azhar

Sanderson, Jeremy

机构：

[1] St Thomas Hosp, Guys & St Thomas Hosp, Dept Gastroenterol, London SE1 7EH, England

[2] Guys Hosp, Purine Res Lab, London SE1 9RT, England

来源：

PERSONALIZED MEDICINE | 2006年 / 3卷 / 01期

关键词：

6-mercaptopurine; adverse effects; azathioprine; drug toxicity; inflammatory bowel disease; inosine triphosphatase; inosine triphosphate; pyrophosphohydrolase; ITPA; ITPase; thiopurine methyl transferase; thiopurine; TPMT;

D O I：

10.2217/17410541.3.1.45

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genetic variation in thiopurine methyltransferase (TPMT) enzyme activity strongly predicts adverse effects in patients treated with the thiopurine drugs, azathioprine and 6-mercaptopurine, and is one of the classic examples of pharmacogenetics in clinical practice. Recently, polymorphic variation in the gene encoding the enzyme inosine triphosphatase (ITPase) has also been associated with risk of thiopurine-related toxicity. This article reviews the evidence for the role of TPMT and ITPase deficiency as predictors of thiopurine toxicity and makes recommendations for clinical and laboratory practice.

引用

收藏

页码：45 / 59

页数：15

相关论文

共 110 条

[1]

Alexander S, 2005, INTERN MED J, V35

[2] ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [J].

Allorge, D ;

Hamdan, R ;

Broly, F ;

Libersa, C ;

Colombel, JF .

GUT, 2005, 54 (04) :565-565

[3] Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity [J].

Alves, S ;

Amorim, A ;

Ferreira, F ;

Prata, MJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :165-174

[4] Thiopurine methyltransferase alleles in British and Ghanaian populations [J].

Ameyaw, MM ;

Collie-Duguid, ESR ;

Powrie, RH ;

Ofori-Adjei, D ;

McLeod, HL .

HUMAN MOLECULAR GENETICS, 1999, 8 (02) :367-370

[5]

[Anonymous], COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000545

[6] Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease [J].

Ansari, A ;

Hassan, C ;

Duley, J ;

Marinaki, A ;

Shobowale-Bakre, EM ;

Seed, P ;

Meenan, J ;

Yim, A ;

Sanderson, J .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) :1743-1750

[7] Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity [J].

Arenas, M ;

Simpson, G ;

Lewis, CM ;

Shobowale-Bakre, EM ;

Escuredo, E ;

Fairbanks, LD ;

Duley, JA ;

Ansari, A ;

Sanderson, JD ;

Marinaki, AM .

CLINICAL CHEMISTRY, 2005, 51 (12) :2371-2374

[8] Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype [J].

Arenas, M ;

Duley, JA ;

Ansari, A ;

Shobowale-Bakre, EA ;

Fairbanks, L ;

Soon, SY ;

Sanderson, J ;

Marinaki, AM .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) :1403-1405

[9] Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: A tertiary referral center experience [J].

Bajaj, JS ;

Saeian, K ;

Varma, RR ;

Franco, J ;

Knox, JF ;

Podoll, J ;

Emmons, J ;

Levy, M ;

Binion, DG .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) :1121-1125

[10] Thiopurine methyltransferase polymorphisms in a Brazilian population [J].

Boson, WL ;

Romano-Silva, MA ;

Correa, H ;

Falcao, RP ;

Teixeira-Vidigal, PV ;

De Marco, L .

PHARMACOGENOMICS JOURNAL, 2003, 3 (03) :178-182

← 1 2 3 4 5 6 7 8 9 10 →